NCT04908735View on ClinicalTrials.gov

Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 12, 2021

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Hematopoietic Stem Cell Transplant (HSCT)Bronchiolitis Obliterans (BO)
Interventions
DRUG

Ruxolitinib

Participants will receive ruxolitinib orally twice daily for 24 weeks.

Trial Locations (3)

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

55455

RECRUITING

University of Minnesota, Minneapolis

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER